Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
Vita E, Monaca F, Milardi D, Mastrantoni L, Stefani A, Vergani E, Russo J, Barone D, Sparagna I, Vitale A, Scala A, Occhipinti D, Di Salvatore M, Pontecorvi A, Tortora G, Bria E. Vita E, et al. Among authors: bria e. Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293. Online ahead of print. Cancer. 2024. PMID: 38549441
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Vita E, Stefani A, Piro G, Mastrantoni L, Cintoni M, Cicchetti G, Sparagna I, Monaca F, Horn G, Russo J, Barone D, Di Salvatore M, Trisolini R, Lococo F, Mazzarella C, Cancellieri A, Carbone C, Larici AR, Mele MC, Pilotto S, Milella M, Tortora G, Bria E. Vita E, et al. Among authors: bria e. Cancer Immunol Immunother. 2023 Nov;72(11):3803-3812. doi: 10.1007/s00262-023-03533-0. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668709 Free PMC article.
Has crizotinib significantly impacted non-small-cell lung cancer therapy?
Vita E, Stefani A, D'Argento E, Tortora G, Bria E. Vita E, et al. Among authors: bria e. Expert Opin Pharmacother. 2020 Nov;21(16):1927-1930. doi: 10.1080/14656566.2020.1796971. Epub 2020 Jul 27. Expert Opin Pharmacother. 2020. PMID: 32717154 No abstract available.
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Ferrara MG, Martini M, D'Argento E, Forcella C, Vita E, Di Noia V, Sperduti I, Bilotta M, Ribelli M, Damiano P, Cannella A, Stefani A, Pilotto S, Carbone C, Piro G, Milella M, Tortora G, Bria E. Ferrara MG, et al. Among authors: bria e. Clin Lung Cancer. 2021 Jul;22(4):351-360. doi: 10.1016/j.cllc.2020.12.008. Epub 2021 Feb 6. Clin Lung Cancer. 2021. PMID: 33558194
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.
Stefani A, Piro G, Schietroma F, Strusi A, Vita E, Fiorani S, Barone D, Monaca F, Sparagna I, Valente G, Ferrara MG, D'Argento E, Di Salvatore M, Carbone C, Tortora G, Bria E. Stefani A, et al. Among authors: bria e. Front Oncol. 2022 Oct 27;12:1026020. doi: 10.3389/fonc.2022.1026020. eCollection 2022. Front Oncol. 2022. PMID: 36387232 Free PMC article. Review.
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Di Noia V, D'Argento E, Pilotto S, Vita E, Ferrara MG, Damiano P, Ribelli M, Cannella A, Virtuoso A, Fattorossi A, Ceresoli GL, Milella M, Beretta GD, Tortora G, Bria E. Di Noia V, et al. Among authors: bria e. Cancer Immunol Immunother. 2021 Jun;70(6):1583-1592. doi: 10.1007/s00262-020-02788-1. Epub 2020 Nov 24. Cancer Immunol Immunother. 2021. PMID: 33231726 Free PMC article. Clinical Trial.
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV, Schino M, Strippoli A, Calegari MA, Cocomazzi A, Cassano A, Pozzo C, Di Salvatore M, Ricci R, Barone C, Bria E, Tortora G, Larocca LM, Basso M, Martini M. Zurlo IV, et al. Among authors: bria e. Cancer Immunol Immunother. 2022 Jan;71(1):45-55. doi: 10.1007/s00262-021-02960-1. Epub 2021 May 19. Cancer Immunol Immunother. 2022. PMID: 34009410 Free PMC article.
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.
Ferrara MG, Stefani A, Pilotto S, Carbone C, Vita E, Di Salvatore M, D'Argento E, Sparagna I, Monaca F, Valente G, Vitale A, Piro G, Belluomini L, Milella M, Tortora G, Bria E. Ferrara MG, et al. Among authors: bria e. Front Oncol. 2021 Dec 23;11:792385. doi: 10.3389/fonc.2021.792385. eCollection 2021. Front Oncol. 2021. PMID: 35004317 Free PMC article. Review.
Long-term survivors with immunotherapy in advanced NSCLC: is 'cure' within reach?
Monteverdi S, Vita E, Sartori G, Ferrara MG, D'Argento E, Tortora G, Milella M, Bria E, Pilotto S. Monteverdi S, et al. Among authors: bria e. Transl Cancer Res. 2020 Feb;9(2):409-414. doi: 10.21037/tcr.2019.12.82. Transl Cancer Res. 2020. PMID: 35117384 Free PMC article. No abstract available.
383 results